Alcon Inc. ALC
NYSEMedical devicesFinancials to Sep 30, 2026 · Updated Nov 11, 2026
Moat ranks
Balance sheet
| $B | Dec 31 | Sep 30 |
|---|---|---|
| Cash | 1.5 | 1.7 |
| Securities | 0.1 | 0.1 |
| Debt | 4.7 | 4.8 |
| Net cash | -3.1 | -3.0 |
| Equity | 22.0 | 21.7 |
- Debt / EBITDA
- 2.17×
- Debt / equity
- 0.22×
- Leases (9/30/26)
- $573M
- Diluted shares
- 483M
- Book value / share
- $44.97
- Price / book
- 1.6×
- Net cash / share
- −$6.12
- Market cap
- $35.6B
- Enterprise value
- $38.6B
Per-share record
Key indicators
| Indicator | Latest | Vs year ago | Last 8 quarters |
|---|---|---|---|
| Revenue growth | 4.7% | -1.8 pts | |
| Operating margin | 13.9% | +1.2 pts | |
| FCF margin | 22.4% | +1.9 pts | |
| Capex / revenue | 5.4% | -1.8 pts | |
| Consumables net sales | $789M | +6% | |
| Surgical equipment and other net sales | $269M | +11% | |
| Contact lenses net sales | $737M | +4% | |
| Ocular health net sales | $500M | +8% | |
| Surgical implantables net sales | $422M | -2% |
Margins and growth from reported quarters; company KPIs as reported in results releases.
About ALC
Alcon sells Surgical and Vision Care products. FY2025 revenue, including other revenue, was $10.401B, split 55.3% Surgical and 44.7% Vision Care.
- Installed Base Consumables
Installed base of ophthalmic surgical equipment with multi-year replacement cycles helps pull recurring sales of procedure-linked consumables.
- Brand Trust
Brand familiarity and trust, reinforced by eye-care-professional recommendations, support premium positioning and customer retention across contact lenses and ocular health.
- Capex Knowhow Scale
Specialized material science, automation, and proprietary manufacturing know-how in contact lenses and ocular products benefit from scale and a global manufacturing footprint.
- Oct 2, 2026
Alcon reported a 256-patient study showing Systane Pro symptom relief was non-inferior to Miebo over one month. The short, company-funded study supports positioning but does not prove long-term superiority.
- Sep 30, 2026 · Gain +$58M
IEEPA refunds: $55m reduction of cost of sales and $3m related interest reported in operating other income. $1m PP&E credit is excluded from profit adjustment.
- Sep 3, 2026
Alcon launched Unity M, a modular surgical microscope with approvals across several major markets, expanding its surgical equipment offering and potential cross-selling.
- Aug 26, 2026
Alcon priced EUR 500M of 3.875% notes due 2033 for general corporate purposes, potentially including refinancing; the debt extends funding availability but creates interest obligations.
- Aug 10, 2026
Alcon increased its 2026 core margin and earnings growth guidance while keeping constant-currency sales growth at 5%-7%, supported by new products and manufacturing efficiency.
Ownership
Go deeper on ALC
- Compare stock research toolsFundamentals, valuation and screening platforms for ALC.19 tools
- See ALC's price chartNo price chart here yet. See price history and indicators.17 tools
- Read ALC's earnings callsTranscripts and audio of results calls, with management's own words.15 tools
- Investing tool dealsCurrent discounts on research, charting and tracking tools.91 deals
On this page
Financial record
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | Trend | Change 2016–25 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Per share ($) | |||||||||||||
| Revenue | – | 13.91 | 14.65 | 15.38 | 13.97 | 16.80 | 17.63 | 19.04 | 19.92 | 20.96 | 22.73 | – | |
| Cash flow | – | 2.49 | 2.34 | 1.88 | 1.68 | 2.73 | 2.46 | 2.80 | 4.17 | 4.58 | 4.86 | – | |
| Earnings | – | 0.52 | -0.46 | -1.34 | -1.09 | 0.76 | 0.68 | 1.96 | 2.05 | 1.98 | 1.38 | – | |
| Free cash flow | – | 1.48 | 0.88 | 0.50 | 0.52 | 0.33 | -0.03 | 1.08 | 2.83 | 3.24 | 3.45 | – | |
| Capex | – | 1.02 | 1.46 | 1.38 | 1.16 | 2.39 | 2.49 | 1.72 | 1.35 | 1.34 | 1.41 | – | |
| Dividends | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 | 0.20 | 0.23 | 0.26 | 0.33 | 0.36 | – | |
| Book value | – | 47.17 | 46.37 | 39.54 | 38.49 | 39.03 | 39.80 | 41.54 | 43.32 | 44.41 | 44.97 | – | |
| Diluted shares (M) | – | 488 | 488 | 488 | 489 | 493 | 494 | 497 | 498 | 496 | 483 | – | |
| Totals ($B) | |||||||||||||
| Revenue | 6.6 | 6.8 | 7.2 | 7.5 | 6.8 | 8.3 | 8.7 | 9.5 | 9.9 | 10.4 | 11.0 | +5.2%/yr | |
| Operating income | 0.0 | -0.1 | -0.2 | -0.2 | -0.5 | 0.6 | 0.7 | 1.0 | 1.4 | 1.4 | 1.0 | +72.6%/yr | |
| Net income | -0.2 | 0.3 | -0.2 | -0.7 | -0.5 | 0.4 | 0.3 | 1.0 | 1.0 | 1.0 | 0.7 | – | |
| Free cash flow | 0.7 | 0.7 | 0.4 | 0.2 | 0.3 | 0.2 | -0.0 | 0.5 | 1.4 | 1.6 | 1.7 | +9.0%/yr | |
| Buybacks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.9 | – | |
| Dividends | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | – | |
| Net cash | – | 0.1 | 0.2 | -2.6 | -2.6 | -2.5 | -3.7 | -3.6 | -2.8 | -3.1 | -3.0 | – | |
| Margins & returns (%) | |||||||||||||
| Gross margin | 47.2 | 47.2 | 44.6 | 48.8 | 43.0 | 56.1 | 54.5 | 55.5 | 55.6 | 55.2 | 57.7 | +8.1 pts | |
| Operating margin | 0.2 | -1.1 | -3.5 | -2.5 | -7.1 | 7.0 | 7.7 | 11.0 | 14.3 | 13.1 | 9.1 | +12.9 pts | |
| Net margin | -2.6 | 3.8 | -3.2 | -8.7 | -7.8 | 4.5 | 3.8 | 10.3 | 10.3 | 9.4 | 6.1 | +12.0 pts | |
| FCF margin | 11.2 | 10.6 | 6.0 | 3.2 | 3.7 | 2.0 | -0.1 | 5.7 | 14.2 | 15.5 | 15.2 | +4.3 pts | |
| ROIC | – | -0.3 | -0.9 | -0.7 | -1.9 | 2.2 | 2.4 | 3.6 | 4.8 | 4.5 | 3.4 | – | |
| Return on equity | -0.7 | 1.1 | -1.0 | -3.4 | -2.8 | 2.0 | 1.7 | 4.7 | 4.7 | 4.4 | 3.1 | +5.2 pts | |
| R&D % of revenue | 7.6 | 8.6 | 8.2 | 8.7 | 9.8 | 10.2 | 8.1 | 8.8 | 8.8 | 9.5 | 13.1 | +2.0 pts | |
| Stock pay % of revenue | 0.8 | 1.0 | 1.3 | 1.5 | 1.7 | 1.8 | 1.7 | 1.7 | 1.6 | 1.6 | 1.6 | +0.8 pts | |
| Capex % of revenue | 7.7 | 7.3 | 10.0 | 9.0 | 8.3 | 14.2 | 14.1 | 9.0 | 6.8 | 6.4 | 6.2 | -1.3 pts | |
Change uses 2016 and 2025 only: compound annual growth for amounts, points for margins and returns, and the change in amount for net cash. A dash means no 2016 base. Trend shows the fiscal years.
Moat
Moat scorecard
- Strength
- Confidence
- Structure
- Oligopoly
- Durability
- durable
- Trajectory
- stable
- Pricing power
- moderate
- Surgical55.3%1 claim
- Vision Care44.7%2 claims
Moat claims
- Applies to
- Surgical
- Confidence
- Durability
- durable
- Trajectory
- stableas of Nov 11, 2026
Installed base of ophthalmic surgical equipment with multi-year replacement cycles helps pull recurring sales of procedure-linked consumables. Implantable lens sales benefit from cross-selling but are not all tied to a proprietary console.
Q3 2026 equipment and other sales were $269 million, up 11%, while consumables reached $789 million, up 6%. New equipment supports repeat supplies, but these sales do not distinguish replacement from incremental placements or prove a wider competitive lead.
- Consumables net sales$789M+6%
- Surgical equipment and other net sales$269M+11%
- Surgical implantables net sales$422M-2%
- Competitors win new platform placements
- Hospital multi-sourcing reduces pull-through
- Pricing pressure from GPOs and tenders
- Procedure volume sensitivity to reimbursement or macro shocks
- FilingAlcon FY2025 Form 20-F (Annual Report)Feb 24, 2026
- SourceFDA Class I Custom Pak recall Z-0939-2026Dec 23, 2025
- SourceFTC statement on Alcon and LENSAR merger abandonmentMar 17, 2026
- NewsAlcon and RxSight adjustable PCIOL collaborationJul 6, 2026
- Applies to
- Vision Care
- Confidence
- Durability
- durable
- Trajectory
- stableas of Nov 11, 2026
Brand familiarity and trust, reinforced by eye-care-professional recommendations, support premium positioning and customer retention across contact lenses and ocular health.
Q3 2026 contact lens sales grew 4% and ocular health grew 8%. Premium mix and dry-eye products support the brand, while declining legacy lenses, customer choice and strong competitors prevent a clear increase in loyalty.
- Contact lenses net sales$737M+4%
- Ocular health net sales$500M+8%
- Retailer/online channel steering to lower-priced alternatives
- Brand churn driven by social and digital marketing
- Private label growth in lens care / ocular health
- FilingAlcon FY2025 Form 20-F (Annual Report)Feb 24, 2026
- Applies to
- Vision Care
- Confidence
- Durability
- durable
- Trajectory
- stableas of Nov 11, 2026
Specialized material science, automation, and proprietary manufacturing know-how in contact lenses and ocular products benefit from scale and a global manufacturing footprint.
Manufacturing efficiencies supported Q3 Vision Care profit, but $55 million of tariff refunds also reduced group cost of sales. Comparable lens unit costs and yields remain undisclosed, so a wider manufacturing cost lead is unproven.
- Contact lenses net sales$737M+4%
- Manufacturing technology diffusion across incumbents
- Quality issues or recalls damage trust and increase costs
- Tariffs, input costs and poor yields can reduce the benefit of scale
- FilingAlcon FY2025 Form 20-F (Annual Report)Feb 24, 2026
Profile change log
- Oct 8, 2026 · business change
Alcon reported a 256-patient study showing Systane Pro symptom relief was non-inferior to Miebo over one month. The short, company-funded study supports positioning but does not prove long-term superiority.
- Oct 8, 2026 · business change
Alcon launched Unity M, a modular surgical microscope with approvals across several major markets, expanding its surgical equipment offering and potential cross-selling.
- Oct 8, 2026 · business change
Alcon priced EUR 500M of 3.875% notes due 2033 for general corporate purposes, potentially including refinancing; the debt extends funding availability but creates interest obligations.
- Oct 8, 2026 · business change
Alcon increased its 2026 core margin and earnings growth guidance while keeping constant-currency sales growth at 5%-7%, supported by new products and manufacturing efficiency.
- Oct 8, 2026 · business change
Alcon discontinued the PowerVision lens programs after inconsistent patient outcomes. A $505M impairment, $103M release of purchase obligations and $115M tax benefit reduced reported Q2 earnings but did not consume cash at closure.
- Oct 8, 2026 · business change
Alcon and RxSight agreed to develop adjustable presbyopia-correcting lenses through a non-exclusive license, with a $60M upfront payment and up to $140M of milestones. Alcon will lead commercialization; clinical success is still unproved.
- Oct 8, 2026 · business change
Alcon and LENSAR terminated their merger after FTC opposition, blocking the planned addition of femtosecond cataract laser technology.
- Oct 8, 2026 · business change
Alcon terminated its proposed STAAR Surgical acquisition after shareholders rejected the transaction, leaving the planned implantable contact lens expansion unrealized.
- Oct 8, 2026 · business change
Alcon recalled certain Custom Pak surgical packs for incomplete seals; the FDA classified the recall as Class I, making packaging quality a concrete risk to surgeon trust.
- Oct 8, 2026 · analyst revision
Verified the existing three moat claims and segment weights; added their trajectories, debate, management and two end markets. Removed inferred 40%-43% Surgical and 19%-21% Vision Care share ranges because rounded market sizes do not establish precise shares. Moat strengths and segment evidence status are unchanged.
- Oct 8, 2026 · analyst revision
Rechecked the surgical installed-base advantage against the latest sales and competition evidence. Changed its trajectory from widening to stable because equipment revenue does not establish net placements or a growing competitive lead. Kept all moat strengths and segment evidence status. Limited the end-market leader lists to Alcon, the only company this source ranks across both complete global markets.
- Oct 8, 2026 · analyst revision
Changed segment weights from first-half 2026 net sales to FY2025 total segment revenue, including other revenue, as reported in annual Note 4. Surgical changed from 55.4234% to 55.3216% and Vision Care from 44.5766% to 44.6784%. Removed contribution-profit shares because they exclude $1.081B of unallocated costs and do not reconcile to group operating profit.
- Oct 8, 2026 · business change
Alcon divested and licensed selected product rights in China to Ocumension for equity and future royalties, recognizing a $57M gain and changing the sales base for later comparisons. Source: 2025 Form 20-F, February 24, 2026, Note 21.3.
- Oct 8, 2026 · business change
Alcon acquired the remaining LumiThera equity for $124M net of acquired cash, adding the Valeda light-based treatment for dry age-related macular degeneration. Future payments can include up to $660M of commercial and $30M of development milestones. Source: 2025 Form 20-F, February 24, 2026, Note 21.1.
- Oct 8, 2026 · business change
Alcon acquired a controlling interest in Aurion for $496M net of acquired cash, reaching 99% of outstanding equity and adding a corneal cell therapy candidate. Clinical and regulatory outcomes will determine its value. Source: 2025 Form 20-F, February 24, 2026, Note 21.1.
- Oct 8, 2026 · business change
Alcon acquired the remaining Cylite equity for $72M net of acquired cash, adding cataract diagnostic technology to its surgical portfolio. Source: 2025 Form 20-F, February 24, 2026, Note 21.1.
Industry & peers
Peer map
Global ophthalmic surgical devices
Manufacturer sales of ophthalmic implantables, consumables and surgical equipment, including associated technical and clinical service, support and training. Includes cataract, vitreoretinal, glaucoma and refractive procedures; excludes spectacle retail and hospital procedure fees.
- Alcon
| Stocks | Moat | Gross m. | Op. m. | |
|---|---|---|---|---|
| ALC | 70 | 57.7% | 9.1% | |
| Industry median | 14 | 75 | 52.1% | 13.3% |
| Sector median | 55 | 76 | 61.5% | 17.3% |
| All stocks median | 398 | 76 | 53.1% | 20.0% |
Moat medians cover every stock. Margin medians count only stocks with collected numbers and need at least three.
Drivers & risks
- Ageing populations increase cataract and retinal disease, supporting procedure demand beyond the economic cycle.
- Long equipment replacement cycles support repeat consumables; faster, reliable procedures can win system placements.
- Premium lenses and minimally invasive glaucoma treatments expand patient-paid product choices when clinical benefits are clear.
- Access to surgeons, surgery centers and reimbursement determines whether unmet need becomes paid procedures.
- Hospitals can postpone equipment purchases when financing costs rise; premium lens and refractive surgery spending is more sensitive to household budgets.
- Reimbursement cuts, tenders and consolidation of providers can reduce supplier prices.
- Clinical failures, sterility defects and recalls can reduce surgeon trust and erase development investment.
- Tariffs and currencies affect global manufacturing costs and reported sales; competing platforms can disrupt incumbent consumable demand.
Bulls & bears
Can Unity equipment placements and new Vision Care products produce durable repeat sales and cash growth after launch spending, tariffs and failed development programs?
Arguments
What to watch
- 1Surgical consumables and equipment net sales, including constant-currency growth
- 2Implantable lens net sales and competitive pressure
- 3Contact lens and ocular health net sales versus declines in legacy products
- 4Operating cash flow after gross equipment and intangible investment
- 5Tariff costs and reported profit versus recurring amortization and program closures
Next check: FY2026 results: verify product-launch conversion, efficiency costs and Neurotech integration; next earnings date unconfirmed.
Sources: company filings and dated sources collected for Find My Moat; market cap as of Nov 10, 2026. Not investment advice.
Free to reuse, commercially too, with a credit link. See the data license.
Moat Score 70/100 by <a href="https://www.findmymoat.com/stocks/XNYS:ALC">Find My Moat</a> (as of September 2026)Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.